International Stem Cell Corporation’s Human Parthenogenetic Stem Cells To Be Used In The Development Of Treatments For Liver Disease

International Stem Cell Corporation (OTCBB:ISCO) announced that its human parthenogenetic stem cell lines will be used in studies aimed at creating liver cells to treat human liver disease. The studies will be carried out under a Material Transfer Agreement between ISCO and the University of California, San Francisco. Holger Willenbring, MD, UCSF assistant professor of surgery, will direct the research. “The fact that Dr.

More: continued here

Filed under: Liver Disease / Hepatitis on May 22nd, 2008